


PRODUCT INFORMATION



Cariprazine

Item No. 31446

CAS Registry No.: 839712-12-8
Formal Name: N'-[trans-4-[2-[4-(2,3-dichlorophenyl)-1-piperazinyl]ethyl]cyclohexyl]-N,N-dimethyl-urea
Synonym: RGH-188
MF: C₂₁H₃₂Cl₂N₄O
FW: 427.4
Purity: ≥95%
UV/Vis.: λ_{max}: 219, 258 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Cariprazine is supplied as a crystalline solid. A stock solution may be made by dissolving the cariprazine in the solvent of choice, which should be purged with an inert gas. Cariprazine is soluble in the organic solvent chloroform at a concentration of 10 mg/ml.

Description

Cariprazine is an atypical antipsychotic.¹ It binds to dopamine D_{2L}, D_{2S}, and D₃ receptors, the serotonin (5-HT) receptor subtypes 5-HT_{1A}, 5-HT_{2A}, and 5-HT_{2B}, and histamine H₁ and sigma-1 (σ₁) receptors (K_s = 0.085-23.44 nM).² Cariprazine is an antagonist of dopamine D₂ and D₃ receptors (K_bs = 0.759 and 0.316 nM, respectively, in dopamine-induced [³⁵S]GTPγS binding assays). It is also a partial agonist at these receptors, stimulating inositol phosphate production in murine A9 cells expressing human D_{2L} receptors (EC₅₀ = 3.16 nM) and inhibiting forskolin-induced cAMP accumulation in CHO cells expressing human D₃ receptors (EC₅₀ = 2.63 nM). Cariprazine inhibits amphetamine-induced hyperactivity and the conditioned avoidance response in rats (ED₅₀s = 0.12 and 0.84 mg/kg, respectively).³ It also inhibits scopolamine-induced learning deficits in a water labyrinth learning test in rats when administered at doses ranging from 0.02 to 0.08 mg/kg. Formulations containing cariprazine have been used in the treatment of schizophrenia, as well as manic, depressive, or mixed episodes associated with bipolar I disorder.

References

1. Mészáros, G.P., Agai-Csongor, E., and Kapás, M. Sensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-RGH-188 in human plasma and urine. *J. Pharm. Biomed. Anal.* **48(2)**, 388-397 (2008).
2. Kiss, B., Horváth, A., Némethy, Z., et al. Cariprazine (RGH-188), a dopamine D₃ receptor-preferring, D₃/D₂ dopamine receptor antagonist-partial agonist antipsychotic candidate: In vitro and neurochemical profile. *J. Pharmacol. Exp. Ther.* **333(1)**, 328-340 (2010).
3. Gyertyán, I., Kiss, B., Sággy, K., et al. Cariprazine (RGH-188), a potent D₃/D₂ dopamine receptor partial agonist, binds to dopamine D₃ receptors *in vivo* and shows antipsychotic-like and procognitive effects in rodents. *Neurochem. Int.* **59(6)**, 925-935 (2011).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/25/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM